BioCentury | Jun 2, 2020
Finance

CAR T play Legend looks to lead trio of biotechs onto NASDAQ

Look for three biotechs to price IPOs on NASDAQ this week, with CAR T company Legend the headliner. The Nanjing-based company, which is spinning out of GenScript Biotech Corp. (HKSE:1548), aims to raise $350 million...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...
BioCentury | May 21, 2020
Product Development

Deal flow, diagnostics and defeating COVID-19: a BioCentury podcast

Venture money is flowing. Deals are being completed at a healthy pace. Diagnostics are sitting in the spotlight. And all the while, there’s no sign of where the bottom of the COVID-19 crisis will be....
BioCentury | May 20, 2020
Deals

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective targeted protein degraders by using its covalent chemistry to engage untapped ubiquitin ligases. Targeted protein degraders typically connect one...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

MyoKardia prices follow-on at a premium  MyoKardia Inc. (NASDAQ:MYOK) raised $551.3 million late Tuesday through the sale of 5.3 million shares at $105 in a bumped-up offering that stands to be the biggest follow-on of...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | May 13, 2020
Regulation

Refusal-to-file letter for BMS-bluebird cell therapy further muddies chances of Celgene payout

Partners BMS and bluebird are insistent that FDA’s refusal-to-file letter for their BCMA-targeting cell therapy is merely the result of a documentation issue that isn’t representative of any larger problem. But the resulting delay, which...
Items per page:
1 - 10 of 3327
BioCentury | Jun 2, 2020
Finance

CAR T play Legend looks to lead trio of biotechs onto NASDAQ

Look for three biotechs to price IPOs on NASDAQ this week, with CAR T company Legend the headliner. The Nanjing-based company, which is spinning out of GenScript Biotech Corp. (HKSE:1548), aims to raise $350 million...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

Assembly Biosciences Inc. (NASDAQ:ASMB) said Richard Colonno will retire as CSO, virology, on June 1. He is succeeded by William Delaney, who spent 20 years at Gilead Sciences Inc. (NASDAQ:GILD), most recently serving as executive...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality. Repare Therapeutics Inc. announced Tuesday it will...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...
BioCentury | May 21, 2020
Product Development

Deal flow, diagnostics and defeating COVID-19: a BioCentury podcast

Venture money is flowing. Deals are being completed at a healthy pace. Diagnostics are sitting in the spotlight. And all the while, there’s no sign of where the bottom of the COVID-19 crisis will be....
BioCentury | May 20, 2020
Deals

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective targeted protein degraders by using its covalent chemistry to engage untapped ubiquitin ligases. Targeted protein degraders typically connect one...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

MyoKardia prices follow-on at a premium  MyoKardia Inc. (NASDAQ:MYOK) raised $551.3 million late Tuesday through the sale of 5.3 million shares at $105 in a bumped-up offering that stands to be the biggest follow-on of...
BioCentury | May 14, 2020
Management Tracks

Jakob Dupont steps down as CMO of Gossamer; plus Ascendis, Seer, Jazz, Dragonfly and more

Immunology, inflammation and oncology company Gossamer Bio Inc. (NASDAQ:GOSS) said CMO Jakob Dupont has stepped down. CEO Sheila Gujrathi will take on the role’s responsibilities; the biotech told BioCentury there are no plans to immediately...
BioCentury | May 13, 2020
Regulation

Refusal-to-file letter for BMS-bluebird cell therapy further muddies chances of Celgene payout

Partners BMS and bluebird are insistent that FDA’s refusal-to-file letter for their BCMA-targeting cell therapy is merely the result of a documentation issue that isn’t representative of any larger problem. But the resulting delay, which...
Items per page:
1 - 10 of 3327